- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evaluating Quality of Life and Adherence With mCRC Treatment Options
Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.
EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC
EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC
EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2
EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions
EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies
EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options
EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care
EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Video content above is prompted by the following:
- What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life?
- What insights can you share related to patient adherence with third-line therapies in metastatic colorectal cancer?
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
